

**Antibiotics**

1. Sung JJ, Wu A, Joynt GM, et al. Severe acute respiratory syndrome: report of treatment and outcome after a major outbreak. *Thorax* 2004;59(5):414-20. **Download the PDF from:** <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1746995/pdf/v059p00414.pdf>

**Chemokines**

1. Glass WG, Subbarao K, Murphy B, Murphy PM. Mechanisms of host defense following severe acute respiratory syndrome-coronavirus (SARS-CoV) pulmonary infection of mice. *Journal of Immunology* 2004;173(6):4030-39. **Download the PDF from:** <http://www.jimmunol.org/content/173/6/4030.full.pdf+html>

2. Wong CK, Lam CW, Wu AK, et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. *Clinical and experimental immunology* 2004;136(1):95-103 doi: 10.1111/j.1365-2249.2004.02415.x[published Online First: Epub Date] | **Download the PDF from:** <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1808997/pdf/cei0136-0095.pdf>

**Convalescent plasma**

1. Cheng Y, Wong R, Soo YO, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. *European journal of clinical microbiology & infectious diseases* : official publication of the European Society of Clinical Microbiology 2005;24(1):44-6 doi: 10.1007/s10096-004-1271-9[published Online First: Epub Date] | **Download the PDF from:** [http://download.springer.com/static/pdf/506/art%253A10.1007%252Fs10096-004-1271-9.pdf?auth66=1362220920\\_4b68188c5ad3755a49b8647b565fa1d9&ext=.pdf](http://download.springer.com/static/pdf/506/art%253A10.1007%252Fs10096-004-1271-9.pdf?auth66=1362220920_4b68188c5ad3755a49b8647b565fa1d9&ext=.pdf) [ON A UNIVERSITY PC/ SUBSCRIPTION ONLY]

2. Yeh KM, Chiueh TS, Siu LK, et al. Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital. *The Journal of antimicrobial chemotherapy* 2005;56(5):919-22 doi: 10.1093/jac/dki346[published Online First: Epub Date] | **Download the PDF from:** <http://jac.oxfordjournals.org/content/56/5/919.full.pdf+html>

3. Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. *PLoS medicine* 2006;3(9):e343 doi: 10.1371/journal.pmed.0030343[published Online First: Epub Date] | **Download the PDF from:** <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1564166/pdf/pmed.0030343.pdf>

4. Wong SSY, Yuen KY. The management of coronavirus infections with particular reference to SARS. *Journal of Antimicrobial Chemotherapy* 2008;62(3):437-41 doi: <http://dx.doi.org/10.1093/jac/dkn243>[published Online First: Epub Date] | **Download the PDF from:** <http://jac.oxfordjournals.org/content/62/3/437.full.pdf+html>

**Corticosteroids**

1. Loutfy MR, Blatt LM, Siminovitch KA, et al. Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. *JAMA : the journal of the American Medical Association* 2003;290(24):3222-8 doi: 10.1001/jama.290.24.3222[published Online First: Epub

Date] | . **Download the PDF from:**

<http://jama.jamanetwork.com/data/Journals/JAMA/4909/JPC30087.pdf>

2. Lee N, Allen Chan KC, Hui DS, et al. Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients. *Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology* 2004;31(4):304-9 doi:

10.1016/j.jcv.2004.07.006[published Online First: Epub Date] | . **Download the PDF from:**

<http://www.sciencedirect.com/science/article/pii/S1386653204001957> [ON A UNIVERSITY PC/SUBSCRIPTION ONLY]

3. Sung JJ, Wu A, Joynt GM, et al. Severe acute respiratory syndrome: report of treatment and outcome after a major outbreak. *Thorax* 2004;59(5):414-20. **Download the PDF from:**

<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1746995/pdf/v059p00414.pdf>

4. Levy MM, Baylor MS, Bernard GR, et al. Clinical issues and research in respiratory failure from severe acute respiratory syndrome. *American journal of respiratory and critical care medicine* 2005;171(5):518-26 doi: 10.1164/rccm.200405-621WS[published Online First: Epub Date] | .

**Download the PDF from:** <http://ajrccm.atsjournals.org/content/171/5/518.full.pdf+html>

5. Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. *PLoS medicine*

2006;3(9):e343 doi: 10.1371/journal.pmed.0030343[published Online First: Epub Date] | . **Download**

**the PDF from:** <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1564166/pdf/pmed.0030343.pdf>

6. Wong SSY, Yuen KY. The management of coronavirus infections with particular reference to SARS. *Journal of Antimicrobial Chemotherapy* 2008;62(3):437-41 doi:

<http://dx.doi.org/10.1093/jac/dkn243>[published Online First: Epub Date] | . **Download the PDF from:**

<http://jac.oxfordjournals.org/content/62/3/437.full.pdf+html>

7. Zhang X, Alekseev K, Jung K, Vlasova A, Hadya N, Saif LJ. Cytokine responses in porcine respiratory coronavirus-infected pigs treated with corticosteroids as a model for severe acute respiratory syndrome. *Journal of virology* 2008;82(9):4420-8 doi: <http://dx.doi.org/10.1128/JVI.02190-07>[published Online First: Epub Date] | . **Download the PDF from:**

<http://europepmc.org/articles/PMC2293053?pdf=render>

## **Cyclosporin**

1. de Wilde AH, Zevenhoven-Dobbe JC, van der Meer Y, et al. Cyclosporin A inhibits the replication of diverse coronaviruses. *The Journal of general virology* 2011;92(Pt 11):2542-8 doi:

10.1099/vir.0.034983-0[published Online First: Epub Date] | . **Download the PDF from:**

<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3352363/>

2. Pfefferle S, Schopf J, Kogl M, et al. The SARS-coronavirus-host interactome: identification of cyclophilins as target for pan-coronavirus inhibitors. *PLoS pathogens* 2011;7(10):e1002331 doi:

10.1371/journal.ppat.1002331[published Online First: Epub Date] | . **Download the PDF from:**

<http://www.plospathogens.org/article/info%3Adoi%2F10.1371%2Fjournal.ppat.1002331>

## **General**

1. Bosma KJ, Taneja R, Lewis JF. Pharmacotherapy for prevention and treatment of acute respiratory distress syndrome: Current and experimental approaches. *Drugs* 2010;70(10):1255-82 doi: <http://dx.doi.org/10.2165/10898570-000000000-00000>[published Online First: Epub Date] |. Abstract only: <http://www.ncbi.nlm.nih.gov/pubmed/20568833>

2. DuVernoy T, Briese T, et al. Panel discussion - Viral respiratory pathogens. *Influenza and other Respiratory Viruses* 2010;4:21-22 doi: <http://dx.doi.org/10.1111/j.1750-2659.2010.00136.x>[published Online First: Epub Date] |. **Download the PDF from:** <http://onlinelibrary.wiley.com/doi/10.1111/j.1750-2659.2010.00136.x/pdf> [UNIVERSITY-NETWORKED PC/ SUBSCRIPTION ONLY; SEE P. 3]

3. Barnard DL, Kumaki Y. Recent developments in anti-severe acute respiratory syndrome coronavirus chemotherapy. *Future Virology* 2011;6(5):615-31 doi: <http://dx.doi.org/10.2217/fvl.11.33>[published Online First: Epub Date] |. **Download the PDF from:** <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3136164/pdf/nihms304163.pdf>

### **Indomethacin**

1. Amici C, Di Caro A, Ciucci A, et al. Indomethacin has a potent antiviral activity against SARS coronavirus. *Antiviral therapy* 2006;11(8):1021-30. **Download the PDF from:** <http://www.intmedpress.com/servefile.cfm?suid=35d8dc5e-70f4-491f-acad-e35f99be9211>

### **Interferon**

1. Loutfy MR, Blatt LM, Siminovitch KA, et al. Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. *JAMA : the journal of the American Medical Association* 2003;290(24):3222-8 doi: 10.1001/jama.290.24.3222[published Online First: Epub Date] |. **Download the PDF from:** <http://jama.jamanetwork.com/data/Journals/JAMA/4909/JPC30087.pdf>

2. Haagmans BL, Kuiken T, Martina BE, et al. Pegylated interferon- $\alpha$  protects type 1 pneumocytes against SARS coronavirus infection in macaques. *Nature medicine* 2004;10(3):290-93 doi: 10.1038/nm1001[published Online First: Epub Date] |. **Download the PDF from:** <http://www.nature.com/nm/journal/v10/n3/pdf/nm1001.pdf> [ON A UNIVERSITY PC/ SUBSCRIPTION ONLY]

3. Sainz B, Jr., Mossel EC, Peters CJ, Garry RF. Interferon-beta and interferon-gamma synergistically inhibit the replication of severe acute respiratory syndrome-associated coronavirus (SARS-CoV). *Virology* 2004;329(1):11-7 doi: 10.1016/j.virol.2004.08.011[published Online First: Epub Date] |. **Download the PDF from:** [http://pdn.sciencedirect.com/science?\\_ob=MiamiImageURL&\\_cid=272412&\\_user=126524&\\_pii=S0042682204005422&\\_check=y&\\_origin=article&\\_zone=toolbar&\\_coverDate=2004--10&\\_view=c&\\_originContentFamily=serial&\\_wchp=dGLzVlt-zSkzV&\\_md5=4dd23a54bf727d8ddbcebfad784b9f61&\\_pid=1-s2.0-S0042682204005422-main.pdf](http://pdn.sciencedirect.com/science?_ob=MiamiImageURL&_cid=272412&_user=126524&_pii=S0042682204005422&_check=y&_origin=article&_zone=toolbar&_coverDate=2004--10&_view=c&_originContentFamily=serial&_wchp=dGLzVlt-zSkzV&_md5=4dd23a54bf727d8ddbcebfad784b9f61&_pid=1-s2.0-S0042682204005422-main.pdf) [ON A UNIVERSITY PC ONLY]

4. Scagnolari C, Vicenzi E, Bellomi F, et al. Increased sensitivity of SARS-coronavirus to a combination of human type I and type II interferons. *Antiviral therapy* 2004;9(6):1003-11. Abstract only: <http://www.ncbi.nlm.nih.gov/pubmed/15651759>
5. Wong CK, Lam CW, Wu AK, et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. *Clinical and experimental immunology* 2004;136(1):95-103 doi: 10.1111/j.1365-2249.2004.02415.x[published Online First: Epub Date] | . **Download the PDF from:** <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1808997/pdf/cei0136-0095.pdf>
6. Gao H, Zhang LL, Wei Q, et al. [Preventive and therapeutic effects of recombinant IFN-alpha2b nasal spray on SARS-CoV infection in Macaca mulata]. *Chung Hua Shih Yen Ho Lin Chuang Ping Tu Hsueh* 2005;19(3):207-10. Abstract only: <http://www.ncbi.nlm.nih.gov/pubmed/16261198>
7. Barnard DL, Day CW, Bailey K, et al. Evaluation of immunomodulators, interferons and known in vitro SARS-coV inhibitors for inhibition of SARS-coV replication in BALB/c mice. *Antivir Chem Chemother* 2006;17(5):275-84. Abstract only: <http://www.ncbi.nlm.nih.gov/pubmed/17176632>
8. Haagmans BL, Osterhaus ADME. Coronaviruses and their therapy. *Antiviral research* 2006;71(2-3 SPEC. ISS.):397-403 doi: 10.1016/j.antiviral.2006.05.019[published Online First: Epub Date] | . **Download the PDF from:** [http://pdn.sciencedirect.com/science?\\_ob=MiamiImageURL&\\_cid=271065&\\_user=126524&\\_pii=S0166354206001707&\\_check=y&\\_origin=article&\\_zone=toolbar&\\_coverDate=30-Sep-2006&\\_view=c&\\_originContentFamily=serial&\\_wchp=dGLbVIV-zSkzk&\\_md5=26b1488e1ded8003a395f5f40e450b8b&\\_pid=1-s2.0-S0166354206001707-main.pdf](http://pdn.sciencedirect.com/science?_ob=MiamiImageURL&_cid=271065&_user=126524&_pii=S0166354206001707&_check=y&_origin=article&_zone=toolbar&_coverDate=30-Sep-2006&_view=c&_originContentFamily=serial&_wchp=dGLbVIV-zSkzk&_md5=26b1488e1ded8003a395f5f40e450b8b&_pid=1-s2.0-S0166354206001707-main.pdf)  
[UNIVERSITY-NETWORKED PC ONLY]
9. Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. *PLoS medicine* 2006;3(9):e343 doi: 10.1371/journal.pmed.0030343[published Online First: Epub Date] | . **Download the PDF from:** <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1564166/pdf/pmed.0030343.pdf>
10. Cervantes-Barragan L, Züst R, Weber F, et al. Control of coronavirus infection through plasmacytoid dendritic-cell- derived type I interferon. *Blood* 2007;109(3):1131-37 doi: 10.1182/blood-2006-05-023770[published Online First: Epub Date] | . **Download the PDF from:** <http://bloodjournal.hematologylibrary.org/content/109/3/1131.full.pdf>
11. Wong SSY, Yuen KY. The management of coronavirus infections with particular reference to SARS. *Journal of Antimicrobial Chemotherapy* 2008;62(3):437-41 doi: <http://dx.doi.org/10.1093/jac/dkn243>[published Online First: Epub Date] | . **Download the PDF from:** <http://jac.oxfordjournals.org/content/62/3/437.full.pdf+html>
12. Danesh A, Cameron CM, Leon AJ, et al. Early gene expression events in ferrets in response to SARS coronavirus infection versus direct interferon-alpha2b stimulation. *Virology* 2011;409(1):102-12 doi: <http://dx.doi.org/10.1016/j.virol.2010.10.002>[published Online First: Epub Date] | . **Download the PDF from:** [http://pdn.sciencedirect.com/science?\\_ob=MiamiImageURL&\\_cid=272412&\\_user=126524&\\_pii=S0042682210006380&\\_check=y&\\_origin=article&\\_zone=toolbar&\\_coverDate=2011--05&\\_view=c&\\_originContentFamily=serial&\\_wchp=dGLbVBA-](http://pdn.sciencedirect.com/science?_ob=MiamiImageURL&_cid=272412&_user=126524&_pii=S0042682210006380&_check=y&_origin=article&_zone=toolbar&_coverDate=2011--05&_view=c&_originContentFamily=serial&_wchp=dGLbVBA-)

[zSkWz&md5=7be2dc3e06c7b3a12b2b68f6df70421c&pid=1-s2.0-S0042682210006380-main.pdf](http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2893.2011.01519.x)

[UNIVERSITY-NETWORKED PC/ SUBSCRIPTION ONLY]

13. Bruno R, Sacchi P, Cima S, et al. Comparison of peginterferon pharmacokinetic and pharmacodynamic profiles. *Journal of viral hepatitis* 2012;19 Suppl 1:33-6 doi: 10.1111/j.1365-2893.2011.01519.x[published Online First: Epub Date] | . **Download the PDF from:**

<http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2893.2011.01519.x/pdf> [UNIVERSITY-NETWORKED PC/ SUBSCRIPTION ONLY]

14. Cameron MJ, Kelvin AA, Leon AJ, et al. Lack of Innate Interferon Responses during SARS Coronavirus Infection in a Vaccination and Reinfection Ferret Model. *PloS one* 2012;7(9) doi:

<http://dx.doi.org/10.1371/journal.pone.0045842>[published Online First: Epub Date] | . **Download the PDF from:** <http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0045842>

### **Intravenous Immunoglobulin**

1. Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. *PLoS medicine* 2006;3(9):e343 doi: 10.1371/journal.pmed.0030343[published Online First: Epub Date] | . **Download the PDF from:** <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1564166/pdf/pmed.0030343.pdf>

### **Mannose-binding lectin**

1. Ip WK, Chan KH, Law HK, et al. Mannose-binding lectin in severe acute respiratory syndrome coronavirus infection. *The Journal of infectious diseases* 2005;191(10):1697-704 doi:

10.1086/429631[published Online First: Epub Date] | . **Download the PDF from:** <http://jid.oxfordjournals.org/content/191/10/1697.full.pdf+html>

2. Zhou Y, Lu K, Pfefferle S, et al. A single asparagine-linked glycosylation site of the severe acute respiratory syndrome coronavirus spike glycoprotein facilitates inhibition by mannose-binding lectin through multiple mechanisms. *Journal of virology* 2010;84(17):8753-64 doi: 10.1128/JVI.00554-10[published Online First: Epub Date] | . **Download the PDF from:**

<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2919028/pdf/0554-10.pdf>

3. Michelow IC, Lear C, Scully C, et al. High-dose mannose-binding lectin therapy for Ebola virus infection. *The Journal of infectious diseases* 2011;203(2):175-9 doi: 10.1093/infdis/jiq025[published Online First: Epub Date] | . **Download the PDF from:**

<http://jid.oxfordjournals.org/content/203/2/175.full.pdf+html>

### **Methylprednisolone**

1. Soo YO, Cheng Y, Wong R, et al. Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. *Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases* 2004;10(7):676-8 doi: 10.1111/j.1469-0691.2004.00956.x[published Online First: Epub Date] | .

**Download the PDF from:** <http://onlinelibrary.wiley.com/doi/10.1111/j.1469-0691.2004.00956.x/pdf>

[ON A UNIVERSITY PC/ SUBSCRIPTION ONLY]

2. Sung JJ, Wu A, Joynt GM, et al. Severe acute respiratory syndrome: report of treatment and outcome after a major outbreak. *Thorax* 2004;59(5):414-20. **Download the PDF from:** <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1746995/pdf/v059p00414.pdf>

### **Polyclonal antibodies**

1. Zhang MY, Choudhry V, Xiao X, Dimitrov DS. Human monoclonal antibodies to the S glycoprotein and related proteins as potential therapeutics for SARS. *Current Opinion in Molecular Therapeutics* 2005;7(2):151-56. Abstract only: <http://www.ncbi.nlm.nih.gov/pubmed/15844623>

### **Protease inhibitor**

1. Chu CM, Cheng VC, Hung IF, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. *Thorax* 2004;59(3):252-6. **Download the PDF from:** <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1746980/pdf/v059p00252.pdf>

2. Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. *PLoS medicine* 2006;3(9):e343 doi: 10.1371/journal.pmed.0030343[published Online First: Epub Date]}. **Download the PDF from:** <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1564166/pdf/pmed.0030343.pdf>

3. Wong SSY, Yuen KY. The management of coronavirus infections with particular reference to SARS. *Journal of Antimicrobial Chemotherapy* 2008;62(3):437-41 doi: <http://dx.doi.org/10.1093/jac/dkn243>[published Online First: Epub Date]}. **Download the PDF from:** <http://jac.oxfordjournals.org/content/62/3/437.full.pdf+html>

4. Barnard DL, Kumaki Y. Recent developments in anti-severe acute respiratory syndrome coronavirus chemotherapy. *Future Virology* 2011;6(5):615-31 doi: <http://dx.doi.org/10.2217/fvl.11.33>[published Online First: Epub Date]}. **Download the PDF from:** <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3136164/pdf/nihms304163.pdf>

### **Ribavirin**

1. van Vonderen MGA, Bos JC, Prins JM, Wertheim-van Dillen P, Speelman P. Ribavirin in the treatment of severe acute respiratory syndrome (SARS). *Neth J Med* 2003;61(7):238-41. **Download the PDF from:** <http://www.njmonline.nl/getpdf.php?t=a&id=62>

2. Lee N, Allen Chan KC, Hui DS, et al. Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients. *Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology* 2004;31(4):304-9 doi: 10.1016/j.jcv.2004.07.006[published Online First: Epub Date]}. **Download the PDF from:** <http://www.sciencedirect.com/science/article/pii/S1386653204001957> [ON A UNIVERSITY PC/ SUBSCRIPTION ONLY]

3. Soo YO, Cheng Y, Wong R, et al. Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. *Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases* 2004;10(7):676-8 doi: 10.1111/j.1469-0691.2004.00956.x[published Online First: Epub Date]}. **Download the PDF from:** <http://onlinelibrary.wiley.com/doi/10.1111/j.1469-0691.2004.00956.x/pdf> [ON A UNIVERSITY PC/ SUBSCRIPTION ONLY]

4. Sung JJ, Wu A, Joynt GM, et al. Severe acute respiratory syndrome: report of treatment and outcome after a major outbreak. *Thorax* 2004;59(5):414-20. **Download the PDF from:** <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1746995/pdf/v059p00414.pdf>

5. Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. *PLoS medicine* 2006;3(9):e343 doi: 10.1371/journal.pmed.0030343[published Online First: Epub Date] | **Download the PDF from:** <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1564166/pdf/pmed.0030343.pdf>

#### **SiRNA**

1. Li BJ, Tang Q, Cheng D, et al. Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque. *Nature medicine* 2005;11(9):944-51 doi: 10.1038/nm1280[published Online First: Epub Date] | **Download the PDF from:** <http://www.nature.com/nm/journal/v11/n9/pdf/nm1280.pdf> [UNIVERSITY-NETWORKED PC/SUBSCRIPTION ONLY]

2. Haagmans BL, Osterhaus ADME. Coronaviruses and their therapy. *Antiviral research* 2006;71(2-3 SPEC. ISS.):397-403 doi: 10.1016/j.antiviral.2006.05.019[published Online First: Epub Date] | **Download the PDF from:** [http://pdn.sciencedirect.com/science?\\_ob=MiamiImageURL&\\_cid=271065&\\_user=126524&\\_pii=S0166354206001707&\\_check=y&\\_origin=article&\\_zone=toolbar&\\_coverDate=30-Sep-2006&\\_view=c&\\_originContentFamily=serial&\\_wchp=dGLbVIV-zSkzk&\\_md5=26b1488e1ded8003a395f5f40e450b8b&\\_pid=1-s2.0-S0166354206001707-main.pdf](http://pdn.sciencedirect.com/science?_ob=MiamiImageURL&_cid=271065&_user=126524&_pii=S0166354206001707&_check=y&_origin=article&_zone=toolbar&_coverDate=30-Sep-2006&_view=c&_originContentFamily=serial&_wchp=dGLbVIV-zSkzk&_md5=26b1488e1ded8003a395f5f40e450b8b&_pid=1-s2.0-S0166354206001707-main.pdf) [UNIVERSITY-NETWORKED PC ONLY]

#### **Viral loads**

1. Hung IF, Cheng VC, Wu AK, et al. Viral loads in clinical specimens and SARS manifestations. *Emerging infectious diseases* 2004;10(9):1550-7 doi: 10.3201/eid1009.040058[published Online First: Epub Date] | **Download the PDF from:** <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3320271/pdf/04-0058.pdf>